Topics

"MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase" Drugs and Medication Database

20:03 EDT 15th September 2019 | BioPortfolio

Here are the most relevant "MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase" Drugs and Medications that we have found in our database.

More Information about "MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase" on BioPortfolio

We have published hundreds of MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase news stories on BioPortfolio along with dozens of MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase Clinical Trials and PubMed Articles about MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase Companies in our database. You can also find out about relevant MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase Drugs and Medications on this site too.

Showing "MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase" Drugs and Medications, all 12

Relevant

Alferon [hemispherx biopharma, inc]

NA

Probably Relevant

Yupelri [the ritedose corporation]

Yupelri (Revefenacin) Inhalation Solution 175 mcg/3 mL

Possibly Relevant

Macrilen [strongbridge u.s. inc]

These highlights do not include all the information needed to use MACRILEN safely and effectively. See full prescribing information for MACRILEN.MACRILEN (macimorelin) for oral solution Initial U.S. Approval: 2017

Keveyis [strongbridge us inc.]

These highlights do not include all the information needed to use KEVEYIS safely and effectively. See full prescribing information for KEVEYIS. KEVEYIS (dichlorphenamide) tablets, for oral use Initial U.S. Approval: 1958

Recombinate [baxter healthcare corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [baxter healthcare corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [baxter healthcare corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Iclusig [millennium pharmaceuticals, inc.]

These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG(ponatinib) tablets, for oral use Initial U.S. Approval: 2012

Eligard [tolmar pharmaceuticals inc.]

These highlights do not include all the information needed to use ELIGARD safely and effectively. See full prescribing information for ELIGARD . ELIGARD (leuprolide acetate for injectable suspension) Initial U.S. Approval: 2002

Mektovi [array biopharma inc.]

These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI. MEKTOVI (binimetinib) tablets, for oral use Initial U.S. Approval: 2018

Vibativ [theravance biopharma r&d, inc.]

These highlights do not include all the information needed to use VIBATIV (telavancin) safely and effectively. See full prescribing information for VIBATIV. VIBATIV (telavancin) for injection, for intravenous useInitial U.S. Approval: 2009 To reduce the d

Sodium thiosulfate [hope pharmaceuticals]

These highlights do not include all the information needed to use the Sodium Thiosulfate Injection safely and effectively. See full prescribing information for Sodium Thiosulfate Injection. Sodium Thiosulfate Injection, USPInitial U.S. Approval: 1992



Quick Search